Chronic Disease Research at an Inflection Point (Virtual)

Tuesday, Oct 29, 2024 at 5:30 PM to 6:30 PM EDT

Register Now
Days
Hours
Minutes
Seconds

Registration

Sale ended

Director's Dialogue with Uli Stilz (Virtual) Partial Approval

Enter your discount code

  • Fee
  • Total amount

1. Select Seats

2. Review and Proceed

Tuesday, Oct 29, 2024 at 5:30 PM to 6:30 PM EDT

Chronic Disease Research at an Inflection Point:
A Conversation with Uli Stilz, VP, Bio Innovation Hub, Novo Nordisk 

Join Ruth Lehmann, Director and President of the Whitehead Institute, in conversation with Uli Stilz, Head of the Novo Nordisk Bio Innovation Hub, as they explore groundbreaking approaches that could transform the treatment of a wide array of medical conditions and reshape the future of patient care.

Live-streamed. Free and open to all.

Cancellation policy

If your plans change and you are no longer able to attend, please cancel by 5:00 pm on Oct. 29.

Whitehead Institute

www.wi.mit.edu

Whitehead Institute is a world-renowned non-profit research institution dedicated to improving human health through basic biomedical research.

Contact the Organizer

Learn more aboutRuth Lehmann Ruth Lehmann
Ruth Lehmann
Director and President
Whitehead Institute

https://wi.mit.edu/people/member/lehmann-director

About Ruth Lehmann

Director and President
Whitehead Institute
Learn more aboutUli Stilz Uli Stilz
Uli Stilz
Head of Bio Innovation Hub
Novo Nordisk

Uli Stilz is Head of Novo Nordisk’s Bio Innovation Hub in Boston. In this role, he is leading a cross functional R&D team developing innovative partnership models with biotech, venture capital, and academia to co-create novel therapies and technologies to provide life changing treatments for people living with cardiometabolic and rare diseases. Uli Stilz graduated with a Master degree in Organic Chemistry from ETH Zürich. He then moved to the Max-Planck-Institute of Biochemistry in Martinsried, where he received his Ph.D. in 1990. After postdoctoral studies at the California Institute of Technology he joined Hoechst AG where he held various positions before he was appointed Associate Vice President of the newly established Innovation unit within the Diabetes Division at Sanofi in 2010. Over a period of 20 years, he contributed to more than 60 preclinical and clinical drug candidates across cardiometabolic, immunology, and oncology therapy areas. Between 2012 and 2014 he was President of the European Federation for Medicinal Chemistry. In 2014, Uli joined Novo Nordisk A/S in Copenhagen and in 2019 relocated to Boston to create and lead the Novo Nordisk Bio Innovation Hub which was established in 2021.

https://www.novonordisk.com/partnering-and-open-innovation/novo-nordisk-bio-innovation-hub.html

About Uli Stilz

Head of Bio Innovation Hub
Novo Nordisk

Comments